Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Nagashima, Masakazu ^a   Takahashi, Hiroshi ^a   Shimane, Kenichi ^a   Nagase, Yuichi ^a   Wauke, Koichi ^b  

^a TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^b Hospitality Care Garden Seisei Rehabilitation Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ETIDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PITAVASTATIN; PREDNISOLONE; PROCOLLAGEN C PROTEINASE; RISEDRONIC ACID; ACID PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOENZYME; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; QUINOLINE DERIVATIVE; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST; PROTEIN BLOOD LEVEL; RADIUS; RHEUMATOID ARTHRITIS; STEROID THERAPY; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOTON ABSORPTIOMETRY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ACID PHOSPHATASE; AGED; ARTHRITIS, RHEUMATOID; BONE DENSITY; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOENZYMES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOGENESIS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; QUINOLINES; RANK LIGAND; TREATMENT OUTCOME;

EID: 84867511743     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4063     Document Type: Article

References (36)

1. Bromeley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in rheumatoid joint. Arthritis Rheum 1984, 27:968-975. 10.1002/art.1780270902, 6236824.
2. Gravallese EM, Harada Y, Wang JT, Corn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951. 1858257, 9546355.
3. Zou W, Hakim I, Tshoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001, 83:70-83. 10.1002/jcb.1202, 11500955.
4. König A, Mühlbauer RC, Fleisch H. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [3H] tetracycline excretion from prelabeled mice. J Bone Miner Res 1988, 3:621-627.
5. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T. Activation of NF-kappa B is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 1998, 273:8799-8805. 10.1074/jbc.273.15.8799, 9535858.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3, 9108485.
7. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X, 9568710.
8. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S. Involvement of receptor activator of nuclear factor-kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269. 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W, 10693864.
9. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285. 10.1007/s002230001146, 11000340.
10. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporosis Int 2000, 11:331-337.
11. Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003, 30:474-479.
12. Yamamoto K, Yoshino S, Shue G, Nagashima M. Inhibitory effect of bone resporption and inflammation with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. Rheumatol Int 2006, 26:627-632. 10.1007/s00296-005-0042-y, 16133581.
13. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949. 10.1126/science.286.5446.1946, 10583956.
14. Maeda T, Matsumura A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 2004, 92:458-471. 10.1002/jcb.20074, 15156558.
15. Koshihara Y, Hoshi K, Okawara R, Ishibashi H, Yamamoto S. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol 2003, 176:339-348. 10.1677/joe.0.1760339, 12630919.
16. Hara K, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 2002, 31:575-581. 10.1016/S8756-3282(02)00874-8, 12477571.
17. Morishita M, Nagashima M, Wauke K, Takahashi H, Takenouchi K. Osteoclast Inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. J Rheumatol 2008, 35:407-413.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
19. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeranyol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999, 96:133-138. 10.1073/pnas.96.1.133, 15105, 9874784.
20. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationship in J774 macrophages. J Bone Miner Res 1998, 13:1668-1678. 10.1359/jbmr.1998.13.11.1668, 9797474.
21. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell RG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589. 10.1359/jbmr.1998.13.4.581, 9556058.
22. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000, 271:688-692. 10.1006/bbrc.2000.2697, 10814523.
23. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001, 110:584-587. 10.1016/S0002-9343(01)00679-9, 11343673.
24. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2diabetes mellitus patients. J Clin Endocrinol Metab 2000, 85:1137-1142. 10.1210/jc.85.3.1137, 10720052.
25. Ste-Marie LG, Sod E, Johnson T, Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:469-476. 10.1007/s00223-004-0039-7, 15478000.
26. Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial. J Bone Miner Metab 2004, 22:469-478.
27. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056. 10.1359/jbmr.2003.18.6.1051, 12817758.
28. Janckila AJ, Neustadt DV, Nakasato YR, Hallen JM, Hentunen T, Yam LT. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 2002, 320:49-58. 10.1016/S0009-8981(02)00026-8, 11983200.
29. Takahashi K, Janckila AJ, Sun SZ, Ledere ED, Ray PC, Yam LT. Electrophoretic study of tartrate-resistant acid phosphatase isoforms in endstage renal disease and rheumatoid arthritis. Clin Chim Acta 2000, 301:147-158. 10.1016/S0009-8981(00)00338-7, 11020469.
30. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001, 47:74-80.
31. Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N- terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporosis Int 2005, 16:1109-1116.
32. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012. 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#, 11352231.
33. Kobayashi A, Hirano F, Makino I. The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheumatol 2005, 34:480-484. 10.1080/03009740510026788, 16393773.
34. Kananen K, Volin L, Laitinen K, Ruutu T, Välimäki MJ. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?. Osteoporosis Int 2006, 17:724-730.
35. Mostaza JM, De la Piedra C, Curiel MD, Reña R, Lahoz C. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clin Chim Acta 2001, 308:133-137. 10.1016/S0009-8981(01)00476-4, 11412825.
36. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, . PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003, 349:1207-1215. 10.1056/NEJMoa031975, 14500804, PaTH Study Investigators.